Which of the following is not considered a first-line therapy for an acute gout flare?

• A. NSAIDs
• B. Colchicine
• C. Allopurinol
• D. Corticosteroids

Answer: (C)

The main idea is that managing an acute gout flare targets rapid inflammation and pain, not long-term urate reduction. Nonsteroidal anti-inflammatory drugs slow prostaglandin production to quickly lessen joint inflammation and fever; colchicine dampens the inflammatory response by inhibiting neutrophil activity, especially effective if given early. Corticosteroids also suppress the inflammatory cascade and can be used when NSAIDs or colchicine aren’t suitable, either systemically or as an intra-articular injection. Allopurinol, on the other hand, lowers uric acid production over time to prevent future attacks, but it does not address the immediate inflammatory process. Initiating or adjusting urate-lowering therapy during an acute attack is generally not appropriate, because it doesn’t relieve the flare promptly and can potentially worsen symptoms; long-term urate management is planned after the attack resolves (while some clinicians may continue an existing allopurinol dose if the patient is already taking it). So the option that is not a first-line acute-treatment choice is the one that works on uric acid levels over the long term, not the immediate inflammation.